ARCHIVES

Lilly Suspends Phase III Trial Of Tasisulam in Melanoma

This article is from The Cancer Letter archive.

Vol. 34 No. 1 | January 28, 2011

Download PDF Visit The Full Archive

Related Articles

In Brief: Fabien Calvo named chief scientific officer of Cancer Core Europe

December 19, 2014

Jako Bows Out with Blast At NCI, Calls For IOM Review Of Cancer Program

April 15, 1988

California Weighs Listing Tamoxifen As Carcinogen

October 27, 1995

Ohio Center Helps Women Stop Smoking, Reduce Cervical Cancer Risk

October 29, 2004

Five-Year Course of Tamoxifen Remains Standard Treatment In HR+ Breast Cancer

July 26, 2002

Centers’ Problems Get Increasing Attention From Staff, Advisors

August 20, 1976